NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS (AMENDMENT) 1984 NO. 169 NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS (AMENDMENT) 1984 NO. 169 - TABLE OF PROVISIONS 1. Commencement 2. Principal Regulations 3. Schedule 1 4. Schedule 2 5. Schedule 3 6. Schedule 5 SCHEDULE 1 SCHEDULE 2 SCHEDULE 3 SCHEDULE 4 1984 No. 169 NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS (AMENDMENT) - REG 1 Commencement 1. These Regulations shall come into operation on 1 August 1984. 1984 No. 169 NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS (AMENDMENT) - REG 2 Principal Regulations 2. In these Regulations, "Principal Regulations" means the National Health (Pharmaceutical Benefits) Regulations. 1984 No. 169 NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS (AMENDMENT) - REG 3 Schedule 1 3. Schedule 1 to the Principal Regulations is amended as set out in Schedule 1. 1984 No. 169 NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS (AMENDMENT) - REG 4 Schedule 2 4. Schedule 2 to the Principal Regulations is amended as set out in Schedule 2. 1984 No. 169 NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS (AMENDMENT) - REG 5 Schedule 3 5. Schedule 3 to the Principal Regulations is amended as set out in Schedule 3. 1984 No. 169 NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS (AMENDMENT) - REG 6 Schedule 5 6. (1) Schedule 5 to the Principal Regulations is amended by omitting "Permanent Head" (wherever occurring) and substituting "Secretary". (2) Schedule 5 to the Principal Regulations is further amended as set out in Schedule 4. 1984 No. 169 NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS (AMENDMENT) - SCHEDULE 1 SCHEDULE 1 Regulation 3 AMENDMENTS OF SCHEDULE 1 TO THE NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS 1. After item 39 insert the following item: "39A Amodiaquine Tablets". 2. After item 113 insert the following item: "113A Bismuth Subgallate". 3. Omit items 284 and 285. 4. Omit item 325. 5. Omit item 338. 6. Omit item 357, substitute the following item: "357 Diphtheria, Tetanus and Pertussis Vaccine". 7. Omit item 485. 8. Omit item 623, substitute the following item: "623 Magnesium Trisilicate Tablets, Compound". 9. Omit items 946 and 947, substitute the following items: "946 Senega Liquid Extract "947 Senega Root". 1984 No. 169 NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS (AMENDMENT) - SCHEDULE 2 SCHEDULE 2 Regulation 4 AMENDMENTS OF SCHEDULE 2 TO THE NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS 1. Omit item 42. 2. After item 77 insert the following items: "77A Dextran 40 Intravenous Infusion, B.P. Anhydrous Glucose, B.P., with Dextran 40 Intravenous Infusion, B.P. Glucose, B.P., with Dextran 40 Intravenous Infusion, B.P. Sodium Chloride, B.P., with Dextran 40 Intravenous Infusion, B.P. "77B Dextran 70 Intravenous Infusion, B.P. Glucose, B.P., with Dextran 70 Intravenous Infusion, B.P. Sodium Chloride, B.P., with Dextran 70 Intravenous Infusion, B.P.". 3. Omit item 88, substitute the following item: "88 Diphenhydramine Hydrochloride, B.P. Ergotamine Tartrate, B.P., with Caffeine Citrate, B.P.C. 1959, and Diphenhydramine Hydrochloride, B.P.". 4. Omit item 91. 5. Omit item 123, substitute the following item: "123 Glucose, Anhydrous, B.P. Dextran 40 Intravenous Infusion B.P., withAnhydrous Glucose, B.P. Sodium Chloride, B.P., Potassium Chloride, B.P., Citric Acid, B.P., Sodium Citrate, B.P., and Anhydrous Glucose, B.P. Sodium Lactate Compound Intravenous Infusion, B.P., with Anhydrous Glucose, B.P.". 6. Omit item 159. 7. Omit item 164. 8. After item 213 insert the following item: "213A Silver Sulphadiazine with Chlorhexidine Gluconate Cream -". 9. Omit item 234. 1984 No. 169 NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS (AMENDMENT) - SCHEDULE 3 SCHEDULE 3 Regulation 5 AMENDMENTS OF SCHEDULE 3 TO THE NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS 1. After item 21 insert the following item: "21A Amiodarone Hydrochloride". 2. Omit item 152. 3. Omit item 155. 4. Omit item 214, substitute the following item: "214 Potassium Chloride, B.P., with Potassium Bicarbonate Effervescent Table ts". 5. After item 224 insert the following item: "224A Ranitidine Hydrochloride". 6. After item 232 insert the following item: "232A Silver Sulphadiazine with Chlorhexidine Gluconate Cream". 1984 No. 169 NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS (AMENDMENT) - SCHEDULE 4 SCHEDULE 4 Regulation 6 AMENDMENTS OF SCHEDULE 5 TO THE NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS 1. After item 6 insert the following item: "6A Amiodarone Hydrochloride With the written authority of the Secretary- For the continuing treatment of severe refractory cardiac arrhythmias where treatment with amiodarone hydrochloride was initiated in a hospital". 2. Omit item 21, substitute the following item: "21 Calcium Carbonate, B.P., with Calcium Lactate-Gluconate With the written authority of the Secretary- Hypocalcaemia Osteoporosis Proven malabsorption". 3. Omit item 28, substitute the following item: "28 Carindacillin Sodium With the written authority of the Secretary- Urinary tract infections where positive bacteriological evidence confirms that carindacillin or carbenicillin is the most appropriate therapeutic agent". 4. Omit items 43 and 43A, substitute the following item: "43 Cimetidine With the written authority of the Secretary- Duodenal ulcer, confirmed by radiology, endoscopy or surgery Gastric ulcer, confirmed by radiology, endoscopy or surgery Zollinger-Ellison syndrome, proven by investigation". 5. Omit item 47, substitute the following item: "47 Codeine Phosphate, B.P., with Aspirin, B.P., Tablets, 30 mg-325 mg With the written authority of the Secretary- Disabling pain associated with proven malignant neoplasia". 6. After item 50 insert the following item: "50A (1) Cyclophosphamide, B. P. (2) Cyclophosphamide Tablets, B.P. With the written authority of the Secretary- Anaemia, autoimmune, haemolytic Arthritis, rheumatoid with vasculitis orvisceral complications Continuing cyclophosphamide therapy initiated in a hospital Dermatomyositis Granulomatosis, Wegener's Hepatitis, active, chronic Lupus erythematosus, systemic Malignant disease including leukaemia Nephritis Nephrotic syndrome Polyarteritis nodosa Scleroderma Thrombocytopenic purpura". 7. Omit item 54, substitute the following item: "54 'DE-LACT INFANT' Acute gastro-enteritis complicated by lactose intolerance in infants who have not attained the age of twelve (12) months Proven lactose intolerance in infants who have not attained the age of twelve (12) months". 8. Omit item 58, substitute the following items: "58 (1) Dextromoramide Tablets, B.P. (2) Dextromoramide Tartrate, B.P. Disabling pain associated with proven malignant neoplasia "58A Diflunisal Tablets, B.P. Chronic osteoarthritis Chronic rheumatoid arthritis". 9. Omit item 65. 10. Omit item 86, substitute the following items: "86 Hydrocortisone Acetate, B. P., Rectal Foam Proctitis Ulcerative colitis "86A Hydrocortisone Acetate Injection, B.P. Alopecia areata For local intra-articular or peri-articular infiltration Granulomata, dermal Keloid Lichen planus hypertrophic Lichen simplex chronicus Lupus erythematosus, chronic discoid". 11. Omit item 96, substitute the following item: "96 Lincomycin Injection, B.P. Gram-positive coccal infections where these cannot be safely and effectively treated with penicillin or a derivative of penicillin". 12. Omit item 102, substitute the following item: "102 Medroxyprogesterone Acetate, B.P., Tablets, 10 mg Breast cancer Dysfunctional uterine bleeding Endometrial cancer Endometriosis Precocious puberty Renal cell cancer Turner's syndrome". 13. Omit item 114, substitute the following item: "114 Metoclopramide Hydrochloride, B.P. With the written authority of the Secretary- Malignant neoplasia (late stage) Gastric stasis due to gastric surgery, diabetic gastroparesis or scleroderma". 14. Omit items 130 and 131, substitute the following item: "130 (1) Oxycodone Hydrochloride (2) Oxycodone Pectinate Disabling pain associated with proven malignant neoplasia". 15. Omit item 151, substitute the following item: "151 Prednisolone Acetate Injection For local intra-articular or peri-articular infiltration". 16. Omit items 161A, 162, 163 and 164, substitute the following items: "161A Ranitidine Hydrochloride With the written authority of the Secretary- Duodenal ulcer, confirmed by radiology, endoscopy or surgery Gastric ulcer, confirmed by radiology, endoscopy or surgery Zollinger-Ellison syndrome, proven by investigation "161B Rifampicin, B.P. With the written authority of the Secretary- Leprosy in adults Prophylaxis of meningococcal disease in close contacts and carriers "162 Silver Sulphadiazine with Chlorhexidine Gluconate Cream With the written authority of the Secretary- Treatment, in a hospital, of burns "163 Sodium Cromoglycate, B.P., Eye Drops With the written authority of the Secretary- Vernal kerato-conjunctivitis "164 Sodium Cromoglycate, B.P., Nebuliser Solution Use in a power-operated nebuliser for prophylaxis of asthma in persons who are unable to use the capsule for oral inhalation". 17. Omit items 166 and 167, substitute the following item: "166 (1) Sodium Valproate, B. P. (2) Sodium Valproate Elixir, B.P. (3) Sodium Valproate Tablets, B.P. Epilepsy". 18. Omit item 184, substitute the following item: "184 Triamcinolone Acetonide, B.P., Injection Alopecia areata For local intra-articular or peri-articular infiltration Granulomata, dermal Keloid Lichen planus hypertrophic Lichen simplex chronicus Lupus erythematosus, chronic discoid Necrobiosis lipoidica Psoriasis". - NOTES 1984 No. 169*1* NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS *2* (AMENDMENT) *1* Notified in the Commonwealth of Australia Gazette on 31 July 1984. *2* Statutory Rules 1960 No. 17 as amended to date. For previous amendments see Note 2 to Statutory Rules 1984 No. 50 and see also Statutory Rules 1984 Nos. 50 and 148.